Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2019

View Archived Issues

Fully human stem cells show heart muscle regeneration promise

Recombinant immunotoxins achieve complete and durable tumor regression in a myeloma mouse model

Amyloid plaques age oligodendrocyte precursors

A novel more relevant model of prostate cancer

LY-3343544, a MET-ADC with potent activity in cancer models

TR1801-ADC shows high efficacy in PDX models of solid tumors

IMGC-936 demonstrates promising antitumor activity in ADAM9-expressing cancer models

Aduro BioTech discovers cyclic GMP-AMP synthase inhibitors

FORMA Therapeutics presents CREB-binding protein and histone acetyltransferase p300 inhibitors

Celldex presents a novel tetravalent human anti-CD27/PD-L1 bispecific antibody, CDX-527

New serine-protein kinase ATM inhibitors identified at AstraZeneca

Jacobio-Alpha Pharmaceuticals, Beijing Jacobio Pharmaceuticals patent FGFR-4 inhibitors

Roche and Genentech disclose complement factor D inhibitors

TQB-3804 demonstrates promising antitumor activity in EGFR-mutant tumor models

Regeneron and Alnylam collaborate to discover, develop and commercialize RNAi therapeutics

Ascentage Pharma and Junshi Bioscience to evaluate the combination of APG-1387 and toripalimab

Diarylquinoline analogues of bedaquiline with improved anti-TB potency and lower cardiotoxicity

OJT-007 and OJT-008 characterized as inhibitors of M. tuberculosis MetAP

Phase II results for benralizumab in PDGFRA-negative hypereosinophilic syndrome

FDA approves Dovato for treatment-naive HIV-1

Topline data from Japanese TIMES 1 study of imeglimin in type 2 diabetes

Poxel reports phase Ia data for MPC inhibitor PXL-065

Phase I trial assesses iC9.GD2.CAR.IL-15 T cells in pediatric relapsed or refractory neuroblastoma

Lixte Biotechnology initiates phase Ib/II study of LB-100 in MDS

Frequency Therapeutics reports phase I/II data on FX-322 for hearing restoration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...